News
L’Oreal awards grants to five postdoctoral female scientists to accelerate research
The candidates were evaluated based on their intellectual merit, research potential and scientific excellence
L’Oréal USA has announced the winners of its annual 2022 For Women in Science (FWIS) fellowship to support research.
This year’s fellows have focused on the areas of biomedical engineering, ecology, mathematics, microbiology, and neuroscience.
The L’Oréal USA For Women in Science programme aims to support innovation, research and women in STEM – science, technology, engineering and mathematics.
The 2022 For Women in Science Fellows include Sikoya Ashburn, whose research in neuroscience focuses on the cerebellum and brain disorders to provide steps toward targeted treatment, Sarah Burnett, whose research in mathematics focuses on the flow of particle-liquid mixtures and Sandya Subramanian, whose research in biomedical engineering addresses at-home management of chronic migraine and Parkinson’s disease through wearable systems.
Other recipients included Margot Wohl, whose research in neuroethology and microbiology focuses on the egg-laying behaviour of mosquitoes and Marina LaForgia, whose research in ecology focuses on seed dispersal of plants to help determine which species will be most vulnerable to environmental change.
David Greenberg, L’Oréal USA’s CEO and president of North America, said: “L’Oréal’s commitment to the cause of women in science runs deep.
“Today, our company continues its proud heritage of advancing scientific knowledge in our industry with a scientific workforce in the US that is comprised of 70 per cent women.
“We are thrilled to recognise the remarkable 2022 class of L’Oréal USA For Women in Science Fellows and showcase their work across a wide range of fields.
“Their work is not only critical to solving our biggest societal challenges today, but also inspiring the next generation of women in STEM.”
The company’s programme, which has seen a nearly US$5m investment in the work of scientists since 2003, aims to build a community of women at the postdoctoral level and empower them to continue their research.
Marissa Pagnani McGowan, L’Oréal’s chief corporate social responsibility and sustainability officer for North America, said: “This year’s L’Oréal USA For Women in Science Fellows exemplify all that we aim to celebrate and accomplish with this programme.
“We believe it’s imperative to create these opportunities and drive visibility to women in STEM for the next generation of girls and young women.
“Every contribution by women in STEM serves as a powerful reminder that the world has been served well by supporting women at these critical junctures in their careers,” she added.
The US For Women in Science Fellowship has so far recognised 95 postdoctoral female scientists, supporting the advancement of research in fields such as neurobiology, metabolic diseases, physics and material science, integrative biology, and biomedical engineering.
The candidates were evaluated based on their intellectual merit, research potential, scientific excellence, and their commitment to supporting women and girls in science.
Applications were reviewed by experienced scientists in the candidates’ respective fields through a partnership with the American Association for the Advancement of Science (AAAS), which manages the application and peer review process.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Menopause3 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Menopause2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now






